More importantly, targeting the complement system through inhibition of complement components, such as C3, C5, C5a and C5aR, has been suggested as a potential therapeutic strategy to reduce hyperinflammation, risk of thrombosis and other complications associated with severe COVID-19 [21,48,50,51,52]. This evidence concerns the gene C3 and COVID-19.